Spots Global Cancer Trial Database for allogeneic
Every month we try and update this database with for allogeneic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders | NCT00636909 | AML ALL CML Chronic Pha... CLL MDS RELAPSED NON-HO... APLASTIC ANEMIA MULTIPLE MYELOM... MYELOPROLIFERAT... | Cyclophosphamid... fludarabine cyclosporine methotrexate G-CSF | - 65 Years | Beth Israel Deaconess Medical Center | |
| Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma | NCT02504359 | Plasma Cell Leu... Recurrent Plasm... | Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus | 18 Years - 65 Years | OHSU Knight Cancer Institute | |
| Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) | NCT00693927 | Hematologic Mal... | Unmanipulated P... CD8-depleted PB... | - 70 Years | University of Liege | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma | NCT01863108 | Melanoma Tumor Vaccines Effects of Immu... | GeniusVac-Mel4 | 18 Years - | University Hospital, Grenoble | |
| Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | NCT00946023 | Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone... | 1 Year - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS | NCT02204020 | Acute Myeloid L... Myelodysplastic... | 5-azacytidine (... | 18 Years - | University of Pittsburgh | |
| Cellular Therapy With Cord Blood Cells | NCT00427557 | Multiple Myelom... Leukemia Lymphoma | Fludarabine Melphalan Umbilical Cord ... Rituximab Peripheral Bloo... | - 80 Years | M.D. Anderson Cancer Center | |
| Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies | NCT02743351 | Hematologic Mal... Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Acute Graft-ver... | ProTmune Control Arm | 18 Years - | Fate Therapeutics | |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | NCT00809276 | Lymphoma Multiple Myelom... Leukemia Myelodysplastic... | Busulfan, Fluda... | - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | NCT05120570 | Acute Leukemia Myelodysplastic... Myeloproliferat... Lymphoma | VIC- 1911 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) | NCT06285422 | Non Hodgkin's L... Large B-cell Ly... | SC262 | 18 Years - 80 Years | Sana Biotechnology | |
| A Long-term Follow-up Study of Patients Who Received VOR33 | NCT05309733 | Leukemia, Myelo... | VOR33 | - | Vor Biopharma | |
| Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | NCT01624701 | Acute Leukemia Chronic Leukemi... Myelodysplastic... Lymphoma Myeloma | Ex vivo expande... | 12 Years - 60 Years | Singapore General Hospital | |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation | NCT01316549 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Fludarabine | - 17 Years | University of California, San Francisco | |
| Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002844 | Leukemia | Cyclophosphamid... Allogeneic Bone... Autologous Bone... Total Body Irra... | 16 Years - 65 Years | M.D. Anderson Cancer Center | |
| A Long-term Follow-up Study of Patients Who Received VOR33 | NCT05309733 | Leukemia, Myelo... | VOR33 | - | Vor Biopharma | |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | NCT05218408 | Astrocytoma, Gr... Glioblastoma Giant Cell Glio... Glioblastoma Mu... | CYNK-001 system... | 18 Years - | Celularity Incorporated | |
| A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia | NCT04822766 | Acute Myeloid L... | Hematopoietic s... Best chemothera... | 65 Years - 75 Years | Assistance Publique - Hôpitaux de Paris | |
| Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002844 | Leukemia | Cyclophosphamid... Allogeneic Bone... Autologous Bone... Total Body Irra... | 16 Years - 65 Years | M.D. Anderson Cancer Center | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | NCT01624701 | Acute Leukemia Chronic Leukemi... Myelodysplastic... Lymphoma Myeloma | Ex vivo expande... | 12 Years - 60 Years | Singapore General Hospital | |
| Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT | NCT01810120 | Acute Lymphobla... Leukemia Acute ... Non-Hodgkin Lym... Myelodysplastic... | TCR alfa beta T... | 3 Months - 20 Years | Bambino Gesù Hospital and Research Institute | |
| Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | NCT02294552 | Acute Myeloid L... Acute Lymphoid ... Lymphoma Myelodysplastic... Chronic Lymphoc... Immune System D... | Cyclophosphamid... Busulfan Fludarabine mon... Tacrolimus Mycophenolate m... Allogeneic hema... | 18 Years - 65 Years | St. Petersburg State Pavlov Medical University | |
| Allogenic Stem Cell Transplantation (SCT) With Non-myeloablative Conditioning in Patients With Relapse Non-Hodgkin's Lymphoma (NHL) | NCT00644371 | Non-Hodgkin Lym... | Ibritumomab Tiu... | 18 Years - 65 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | NCT01135329 | Lymphoma Leukemia Myelodysplastic... | Fludarabine Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) | NCT04438083 | Renal Cell Carc... | CTX130 | 18 Years - | CRISPR Therapeutics | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies | NCT01036009 | Acute Leukemia Acute Myeloid L... Acute Lymphobla... Biphenotypic Le... Pre-leukemic Sy... Monosomy 7 Bone Marrow Clo... Juvenile Myelom... Myelodysplastic... Chronic Myeloge... | Withdrawal of i... | 6 Months - 25 Years | University of California, San Francisco | |
| Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation | NCT01316549 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi Anemia Thalassemia Sickle Cell Dis... | Fludarabine | - 17 Years | University of California, San Francisco | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | NCT04489420 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Cyclophosphamid... Immunosuppressi... Immunologic Fac... Physiological E... Molecular Mecha... Antiviral Agent... Anti-infective ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... | CYNK001-IV CYNK001-IT | 18 Years - | Celularity Incorporated | |
| Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | NCT01624701 | Acute Leukemia Chronic Leukemi... Myelodysplastic... Lymphoma Myeloma | Ex vivo expande... | 12 Years - 60 Years | Singapore General Hospital | |
| UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies | NCT05015972 | B-cell Lymphoma | CTA30X UCAR-T i... | 3 Years - 70 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
| Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | NCT01326728 | Chronic Myeloge... Acute Myelogeno... Acute Lymphobla... Hodgkins Lympho... Non-Hodgkins Ly... | Allogeneic stem... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | NCT03480360 | Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Myelodysplasia Myeloproliferat... Myelofibrosis Lymphoma Lymphoma, Non-H... Plasma Cell Dis... | Cyclophosphamid... Fludarabine Total Body Irra... Tacrolimus cellcept g-csf Peripheral Bloo... | 18 Years - 75 Years | Dartmouth-Hitchcock Medical Center | |
| Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | NCT05628545 | Advanced Hepato... | GDKM-100 inject... | 18 Years - 75 Years | Guangdong GD Kongming Biotech LLC | |
| Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | NCT06285422 | Non Hodgkin's L... Large B-cell Ly... | SC262 | 18 Years - 80 Years | Sana Biotechnology | |
| Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe) | NCT04942730 | Leukemia, Acute... Myeloid Leukemi... Biphenotypic Ac... Lymphoblastic L... Myelodysplastic... Myeloproliferat... | Fludarabine Bendamustine Hy... Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus 5Mg ... | 18 Years - 75 Years | St. Petersburg State Pavlov Medical University | |
| NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents | NCT02763475 | Acute Myeloid L... Leukemia Myeloid Leukemi... | cyclophosphamid... Fludarabine NK cell infusio... IL-2 | - 21 Years | Instituto de Investigación Hospital Universitario La Paz | |
| Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients | NCT03609827 | Hematologic Mal... Nonmalignant Di... Immunodeficienc... Hemoglobinopath... Genetic Inborn ... Fanconi's Anemi... Thalassemia Sickle Cell Dis... | Melphalan | - 17 Years | University of California, San Francisco | |
| A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma | NCT04244656 | Multiple Myelom... | CTX120 | 18 Years - | CRISPR Therapeutics | |
| UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies | NCT05015972 | B-cell Lymphoma | CTA30X UCAR-T i... | 3 Years - 70 Years | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | |
| Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation | NCT01596699 | Myeloid Maligna... Bone Marrow Fai... Transfusion-dep... Congenital Immu... Metabolic Disea... Severe Immune D... | Alemtuzumab Busulfan Fludarabine Clofarabine | 3 Months - 30 Years | University of California, San Francisco | |
| Mismatched Donor Cells to Treat Acute Myeloid Leukemia | NCT01793025 | Acute Myeloid L... | ATAC Therapy | 18 Years - | Maisonneuve-Rosemont Hospital | |
| Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | NCT00285259 | Acute Lymphobla... Chronic Myeloge... Acute Myelogeno... Hodgkin's Lymph... Non-Hodgkin's L... Myelodysplastic... | VCL-CB01 Phosphate-buffe... | 18 Years - 65 Years | Astellas Pharma Inc | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | NCT02556931 | Myelodysplastic... Chronic Myelomo... Small Lymphocyt... Chronic Lymphoc... Prolymphocytic ... Chronic Myeloid... Chronic Myelopr... Multiple Myelom... Plasma Cell Neo... Plasma Cell Dys... Myelofibrosis Polycythemia Ve... Essential Throm... Plasma Cell Leu... | Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate m... | - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas | NCT00998361 | Ewing Soft Tissue Sar... | Allogeneic hemo... | 1 Month - 60 Years | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma | NCT00948922 | Multiple Myelom... | Bortezomib Melphalan Autologous Stem... Fludarabine Allogeneic Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | NCT05120570 | Acute Leukemia Myelodysplastic... Myeloproliferat... Lymphoma | VIC- 1911 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type | NCT05218408 | Astrocytoma, Gr... Glioblastoma Giant Cell Glio... Glioblastoma Mu... | CYNK-001 system... | 18 Years - | Celularity Incorporated | |
| Stem Cell Translpantation in Multiple Myeloma | NCT05082675 | Multiple Myelom... | HLA Matched all... | 18 Years - 70 Years | European Society for Blood and Marrow Transplantation | |
| Allo SCT in Amyloidosis Non-interventional Study | NCT02257905 | AL Amyloidosis | 18 Years - 60 Years | European Society for Blood and Marrow Transplantation | ||
| Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs | NCT05423691 | Myelofibrosis | CK0804 | 18 Years - | Cellenkos, Inc. | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia | NCT04106076 | Acute Myeloid L... | UCART123 | 18 Years - 65 Years | Cellectis S.A. | |
| Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | NCT04849910 | Leukemia, Myelo... Myelodysplastic... | VOR33 Mylotarg | 18 Years - 70 Years | Vor Biopharma | |
| Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN | NCT03203369 | Blastic Plasmac... | UCART123 | 18 Years - 80 Years | Cellectis S.A. | |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) | NCT04502446 | T Cell Lymphoma | CTX130 | 18 Years - | CRISPR Therapeutics | |
| Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN | NCT03203369 | Blastic Plasmac... | UCART123 | 18 Years - 80 Years | Cellectis S.A. | |
| A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | NCT03114865 | Acute Lymphobla... B-cell Non Hodg... Pre B-Cell Acut... | Blinatumomab 9u... Blinatumomab 28... Blinatumomab Dexamethasone | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer | NCT03735290 | Carcinoma, Squa... Gastric Adenoca... Gastroesophagea... Non-small Cell ... | ilixadencel Pembrolizumab | 18 Years - | Mendus | |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | NCT01135329 | Lymphoma Leukemia Myelodysplastic... | Fludarabine Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Mismatched Donor Cells to Treat Acute Myeloid Leukemia | NCT01793025 | Acute Myeloid L... | ATAC Therapy | 18 Years - | Maisonneuve-Rosemont Hospital | |
| Stem Cell Translpantation in Multiple Myeloma | NCT05082675 | Multiple Myelom... | HLA Matched all... | 18 Years - 70 Years | European Society for Blood and Marrow Transplantation | |
| Stem Cell Injection in Cancer Survivors | NCT02509156 | Cardiomyopathy ... | Allo-MSCs Placebo | 18 Years - 79 Years | The University of Texas Health Science Center, Houston | |
| Unrelated Donor Stem Cell Transplantation | NCT01364363 | Severe Aplastic... Paroxysmal Noct... Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Myeloproliferat... Chronic Myeloge... Hodgkin's Lymph... Non-Hodgkin's L... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Large Granulocy... | Allogeneic tran... | 18 Years - 69 Years | Scripps Health | |
| Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | NCT05984199 | Leukemia, Myelo... | VCAR33 | 18 Years - | Vor Biopharma | |
| Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient | NCT03806764 | Cytomegalovirus... Haematological ... Organ or Tissue... Immune Suppress... | Blood sampling | 18 Years - | Melbourne Health | |
| PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation | NCT05120570 | Acute Leukemia Myelodysplastic... Myeloproliferat... Lymphoma | VIC- 1911 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies | NCT04943757 | Myeloid Leukemi... Chronic Myeloid... Myelodysplastic... Myeloproliferat... | Bendamustine Hy... Cyclophosphamid | 18 Years - 70 Years | St. Petersburg State Pavlov Medical University | |
| Study of GDX012 in Patients With MRD Positive AML | NCT05001451 | Acute Myeloid L... | GDX012 Suspensi... | 18 Years - | GammaDelta Therapeutics Limited |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
